静注用免疫グロブリンの世界市場レポート 2025年

静注用免疫グロブリンの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.8％で220億1,000万米ドルに成長します。予測期間の成長は、自己免疫疾患の発生率の増加、免疫学の進行中の研究、医療費の増加、がんの発生率の増加、免疫グロブリン製品の革新、個別化医療アプローチに起因しています。予測期間における主な動向としては、原発性免疫不全症（PIDD）治療、急速な技術革新、戦略的提携やパートナーシップ、製造プロセスの進歩、神経学での適応、血液学での使用、免疫療法の進歩などが挙げられます。

老年人口の増加は、今後数年間の静注用免疫グロブリン市場を促進すると予想されます。老年人口は65歳以上の高齢者と定義されます。高齢になるにつれ、免疫システムはしばしば機能しなくなり、抗体の欠乏につながります。その結果、必要な抗体を供給するための免疫グロブリンに対するニーズが高まっています。このような点滴用免疫グロブリンに対する需要の増加が、市場の成長に寄与しています。例えば、ケニアを拠点とする非営利団体人口問題研究所は2024年1月、65歳以上のアメリカ人人口が2022年の5,800万人から2050年には8,200万人へと47%増加すると予測していると報告しています。さらに、この年齢層が全人口に占める割合も、同時期に17％から23％に増加すると予想されています。したがって、老年人口の拡大が静注用免疫グロブリン市場の成長を牽引することになります。

関節リウマチ（RA）の有病率の上昇は、今後数年間の静注用免疫グロブリン（IVIG）市場の成長を促進すると予想されます。RAは、関節の炎症、痛み、腫れ、こわばりを引き起こす慢性的な自己免疫疾患です。未治療の場合、重大な関節障害や身体障害を引き起こす可能性があります。健康なドナーからの抗体を含む血液製剤であるIVIGは、RA患者の関節損傷の原因となる炎症プロセスを緩和するのに役立ちます。例えば、2023年6月、オーストラリアの政府機関であるAustralian Institute of Health and Welfareは、約456,000人のオーストラリア人（1.9％）が関節リウマチに罹患していると推定されると報告しました。2022年には、RAは全疾患負担の2.0％、筋骨格系疾患全体の負担の16％を占めていました。さらに2022年7月、英国の非営利団体である国立関節リウマチ協会（NRAS）は、英国では45万人以上が関節リウマチと共存しており、最も多い発症年齢は40～60歳、男性ではそれよりやや高い年齢であると推定しています。このように、関節リウマチの有病率の増加が静注用免疫グロブリン（IVIG）市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の静注用免疫グロブリンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の静注用免疫グロブリン市場：成長率分析
• 世界の静注用免疫グロブリン市場の実績：規模と成長, 2019-2024
• 世界の静注用免疫グロブリン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の静注用免疫グロブリン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の静注用免疫グロブリン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• IgG（免疫グロブリンG）
• IgM（免疫グロブリンM）
• IgA（免疫グロブリンA）
• IgE（免疫グロブリンE）
• IgD（免疫グロブリンD）
• 世界の静注用免疫グロブリン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の静注用免疫グロブリン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低ガンマグロブリン血症
• 慢性炎症性脱髄性多発神経炎（CIDP）
• 原発性免疫不全症
• 重症筋無力症
• 多巣性運動神経障害
• その他の用途
• 世界の静注用免疫グロブリン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ケア
• 世界の静注用免疫グロブリン市場：免疫グロブリンG（IgG）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 正常IgG
• 特異的IgG
• 世界の静注用免疫グロブリン市場：免疫グロブリンM（IgM）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 正常IgM
• 特異的IgM
• 世界の静注用免疫グロブリン市場：免疫グロブリンA（IgA）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 正常IgA
• 特異的IgA
• 世界の静注用免疫グロブリン市場：免疫グロブリンE（IgE）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 正常IgE
• 特異的IgE
• 世界の静注用免疫グロブリン市場：免疫グロブリンD（IgD）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 正常IgD
• 特異的IgD

第7章 地域別・国別分析

• 世界の静注用免疫グロブリン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の静注用免疫グロブリン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 静注用免疫グロブリン市場：競合情勢
• 静注用免疫グロブリン市場：企業プロファイル
  • Bio Products Laboratory Limited Overview, Products and Services, Strategy and Financial Analysis
  • Biotest AG Overview, Products and Services, Strategy and Financial Analysis
  • China Biologic Products Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • CSL Behring Overview, Products and Services, Strategy and Financial Analysis
  • Grifols S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Kedrion SpA
• Shanghai RAAS Blood Products Co. Ltd.
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc.
• LFB Biotechnologies SAS
• BDI Pharma Inc.
• Hualan Biological Engineering Inc.
• ADMA Biologics Inc.
• Bharat Serums and Vaccines Limited
• Sanquin Plasma Products B.V.
• Prothya Biosolutions B.V.
• Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Kedrion Biopharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 静注用免疫グロブリン市場2029：新たな機会を提供する国
• 静注用免疫グロブリン市場2029：新たな機会を提供するセグメント
• 静注用免疫グロブリン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Intravenous immunoglobulin therapy serves as a treatment for individuals with immunodeficiencies, administered through intravenous infusion. The infusion liquid derives from purified immunoglobulins sourced from healthy donors, rigorously cleansed to eliminate any potential blood-borne infections or impurities.

Key categories of intravenous immunoglobulins encompass IgG, IgM, IgA, IgE, and IgD. IgG, the prevalent immunoglobulin in bodily fluids, plays a pivotal role in safeguarding against bacterial and viral infections. Its application involves reinforcing the body's innate defense mechanisms. These products find distribution channels across hospital and retail pharmacies, serving various medical needs like hypogammaglobulinemia, CIDP, primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, among others. The end-users span hospitals, clinics, and home care setups.

The intravenous immunoglobulin market research report is one of a series of new reports from The Business Research Company that provides intravenous immunoglobulin market statistics, including intravenous immunoglobulin industry global market size, regional shares, competitors with an intravenous immunoglobulin market share, detailed intravenous immunoglobulin market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous immunoglobulin industry. This intravenous immunoglobulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intravenous immunoglobulin market size has grown strongly in recent years. It will grow from $14.66 billion in 2024 to $15.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to treatment of primary immunodeficiency disorders, management of neurological disorders, rising geriatric population, advancements in plasma fractionation techniques, expanded indications in neurology, treatment of infectious diseases, pediatric immunodeficiency treatment.

The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $22.01 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing incidence of autoimmune disorders, ongoing research in immunology, rising healthcare expenditure, growth in cancer incidence, innovation in immunoglobulin products, personalized medicine approaches. Major trends in the forecast period include primary immunodeficiency disorders (PIDD) treatment, rapid technological innovations, strategic collaborations and partnerships, advancements in manufacturing processes, indications in neurology, use in hematology, advances in immunotherapy.

The growing geriatric population is anticipated to propel the intravenous immunoglobulin market in the coming years. The geriatric population is defined as individuals aged 65 and older. As people age, their immune systems often become less effective, leading to a deficiency in antibodies. Consequently, there is a heightened need for immunoglobulins to provide these necessary antibodies. This increasing demand for intravenous immunoglobulins contributes to the market's growth. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, reported that the population of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Additionally, the proportion of this age group within the overall population is expected to grow from 17% to 23% during the same timeframe. Therefore, the expanding geriatric population is set to drive the growth of the intravenous immunoglobulin market.

The rising prevalence of rheumatoid arthritis (RA) is expected to drive the growth of the intravenous immunoglobulin (IVIG) market in the coming years. RA is a chronic autoimmune condition that leads to inflammation, pain, swelling, and stiffness in the joints. If untreated, it can result in significant joint damage and disability. IVIG, a blood product containing antibodies from healthy donors, can help mitigate the inflammatory processes that contribute to joint damage in RA patients. For instance, in June 2023, the Australian Institute of Health and Welfare, a government agency in Australia, reported that approximately 456,000 Australians (1.9%) are estimated to have rheumatoid arthritis. In 2022, RA was responsible for 2.0% of the total disease burden and 16% of the overall burden of musculoskeletal diseases. Furthermore, in July 2022, the National Rheumatoid Arthritis Society (NRAS), a UK-based nonprofit organization, estimated that over 450,000 individuals in the UK are living with rheumatoid arthritis, with the most common onset age being between 40 and 60, or slightly older for men. Thus, the increasing prevalence of rheumatoid arthritis is driving growth in the intravenous immunoglobulin (IVIG) market.

Product innovation is a significant trend gaining traction in the intravenous immunoglobulin (IVIG) market. Key players in the industry are concentrating on developing new products, such as liquid immune globulin formulations, to treat immunodeficiency diseases and maintain their competitive edge. For example, in December 2023, GC Pharma, a pharmaceutical company based in South Korea, launched Alyglo, a sterile, ready-to-use liquid formulation that has received approval from the U.S. Food and Drug Administration (FDA). This product contains 10% immunoglobulin G (IgG), providing 100 mg/mL of protein, of which at least 96% is human IgG derived from pooled human plasma. Alyglo is specifically indicated for treating primary humoral immunodeficiency (PI) in adults aged 17 years and older, addressing conditions such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Major companies in the intravenous immunoglobulin (IVIG) market are concentrating on launching innovative products, such as plasma-derived medicines, and securing approvals from federal agencies like the U.S. Food and Drug Administration (FDA) to enhance their competitive position. The introduction of an FDA-approved innovative IVIG solution represents the official endorsement of a new intravenous immunoglobulin therapy by the FDA for treating specific medical conditions. For instance, in June 2024, Biotest AG, a Germany-based supplier of plasma proteins and products, announced that it received its first FDA approval for Yimmugo, designed to treat primary immunodeficiencies (PIDs). As an intravenous immunoglobulin, Yimmugo contains pooled human plasma-derived immunoglobulin G (IgG), which is essential for providing immune support to patients with PIDs. This approval aligns with the growing demand for plasma-derived therapies, emphasizing the need for effective treatments for patients with weakened immune systems. Yimmugo expands Grifols' existing portfolio of intravenous and subcutaneous immunoglobulins, offering more options for patients dependent on these vital medications.

In February 2024, Ridgemont Equity Partners, a U.S.-based equity investment firm, acquired American Outcomes Management for an undisclosed amount. This acquisition supports Ridgemont's strategic focus on the expanding specialty infusion market, which is fueled by an aging population with chronic conditions and an increasing demand for at-home treatment options. American Outcomes Management is a U.S.-based provider of intravenous immunoglobulin (IVIG) infusion therapy.

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the intravenous immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intravenous immunoglobulin market consists of sales of intravenous immunoglobulin used for treating people with antibody deficiencies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intravenous Immunoglobulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intravenous immunoglobulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intravenous immunoglobulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intravenous immunoglobulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: IgG (Immunoglobulin G); IgM (Immunoglobulin M); IgA (Immunoglobulin A); IgE (Immunoglobulin E); IgD (Immunoglobulin D)
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
• 3) By Application: Hypogammaglobulinemia; Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); Primary Immunodeficiency Diseases; Myasthenia Gravis; Multifocal Motor Neuropathy; Other Applications
• 4) By End-User: Hospitals; Clinics; Home Care
• Subsegments:
• 1) By Immunoglobulin G (IgG): Normal IgG; Specific IgG
• 2) By Immunoglobulin M (IgM): Normal IgM; Specific IgM
• 3) By Immunoglobulin A (IgA): Normal IgA; Specific IgA
• 4) By Immunoglobulin E (IgE): Normal IgE; Specific IgE
• 5) By Immunoglobulin D (IgD): Normal IgD; Specific IgD
• Companies Mentioned: Bio Products Laboratory Limited; Biotest AG; China Biologic Products Holdings Inc.; CSL Behring; Grifols S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Intravenous Immunoglobulin Market Characteristics

3. Intravenous Immunoglobulin Market Trends And Strategies

4. Intravenous Immunoglobulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Intravenous Immunoglobulin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Intravenous Immunoglobulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Intravenous Immunoglobulin Market Growth Rate Analysis
• 5.4. Global Intravenous Immunoglobulin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Intravenous Immunoglobulin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Intravenous Immunoglobulin Total Addressable Market (TAM)

6. Intravenous Immunoglobulin Market Segmentation

• 6.1. Global Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IgG (Immunoglobulin G)
• IgM (Immunoglobulin M)
• IgA (Immunoglobulin A)
• IgE (Immunoglobulin E)
• IgD (Immunoglobulin D)
• 6.2. Global Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.3. Global Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypogammaglobulinemia
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Primary Immunodeficiency Diseases
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• Other Applications
• 6.4. Global Intravenous Immunoglobulin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care
• 6.5. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin G (IgG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal IgG
• Specific IgG
• 6.6. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin M (IgM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal IgM
• Specific IgM
• 6.7. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin A (IgA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal IgA
• Specific IgA
• 6.8. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin E (IgE), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal IgE
• Specific IgE
• 6.9. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin D (IgD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal IgD
• Specific IgD

7. Intravenous Immunoglobulin Market Regional And Country Analysis

• 7.1. Global Intravenous Immunoglobulin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Intravenous Immunoglobulin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intravenous Immunoglobulin Market

• 8.1. Asia-Pacific Intravenous Immunoglobulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intravenous Immunoglobulin Market

• 9.1. China Intravenous Immunoglobulin Market Overview
• 9.2. China Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intravenous Immunoglobulin Market

• 10.1. India Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intravenous Immunoglobulin Market

• 11.1. Japan Intravenous Immunoglobulin Market Overview
• 11.2. Japan Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intravenous Immunoglobulin Market

• 12.1. Australia Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intravenous Immunoglobulin Market

• 13.1. Indonesia Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intravenous Immunoglobulin Market

• 14.1. South Korea Intravenous Immunoglobulin Market Overview
• 14.2. South Korea Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intravenous Immunoglobulin Market

• 15.1. Western Europe Intravenous Immunoglobulin Market Overview
• 15.2. Western Europe Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intravenous Immunoglobulin Market

• 16.1. UK Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intravenous Immunoglobulin Market

• 17.1. Germany Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intravenous Immunoglobulin Market

• 18.1. France Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intravenous Immunoglobulin Market

• 19.1. Italy Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intravenous Immunoglobulin Market

• 20.1. Spain Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intravenous Immunoglobulin Market

• 21.1. Eastern Europe Intravenous Immunoglobulin Market Overview
• 21.2. Eastern Europe Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intravenous Immunoglobulin Market

• 22.1. Russia Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intravenous Immunoglobulin Market

• 23.1. North America Intravenous Immunoglobulin Market Overview
• 23.2. North America Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intravenous Immunoglobulin Market

• 24.1. USA Intravenous Immunoglobulin Market Overview
• 24.2. USA Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intravenous Immunoglobulin Market

• 25.1. Canada Intravenous Immunoglobulin Market Overview
• 25.2. Canada Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intravenous Immunoglobulin Market

• 26.1. South America Intravenous Immunoglobulin Market Overview
• 26.2. South America Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intravenous Immunoglobulin Market

• 27.1. Brazil Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intravenous Immunoglobulin Market

• 28.1. Middle East Intravenous Immunoglobulin Market Overview
• 28.2. Middle East Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intravenous Immunoglobulin Market

• 29.1. Africa Intravenous Immunoglobulin Market Overview
• 29.2. Africa Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intravenous Immunoglobulin Market Competitive Landscape And Company Profiles

• 30.1. Intravenous Immunoglobulin Market Competitive Landscape
• 30.2. Intravenous Immunoglobulin Market Company Profiles
  • 30.2.1. Bio Products Laboratory Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Biotest AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. China Biologic Products Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. CSL Behring Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Grifols S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Intravenous Immunoglobulin Market Other Major And Innovative Companies

• 31.1. Kedrion SpA
• 31.2. Shanghai RAAS Blood Products Co. Ltd.
• 31.3. Octapharma AG
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Baxter International Inc.
• 31.6. LFB Biotechnologies SAS
• 31.7. BDI Pharma Inc.
• 31.8. Hualan Biological Engineering Inc.
• 31.9. ADMA Biologics Inc.
• 31.10. Bharat Serums and Vaccines Limited
• 31.11. Sanquin Plasma Products B.V.
• 31.12. Prothya Biosolutions B.V.
• 31.13. Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.
• 31.14. Pfizer Inc.
• 31.15. Kedrion Biopharma

32. Global Intravenous Immunoglobulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intravenous Immunoglobulin Market

34. Recent Developments In The Intravenous Immunoglobulin Market

35. Intravenous Immunoglobulin Market High Potential Countries, Segments and Strategies

• 35.1 Intravenous Immunoglobulin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Intravenous Immunoglobulin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Intravenous Immunoglobulin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer